Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference

Tuesday, November 7, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

LEXINGTON, Mass., Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a

clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced that Todd C. Brady, M.D., Ph.D., President
and CEO of Aldeyra, will present and host one-on-one meetings at the Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017.

Event: The Stifel 2017 Healthcare Conference

Date: Tuesday, November 14, 2017

Time: 5:00 PM ET

Location: The Lotte New York Palace Hotel in New York City

About Aldeyra TherapeuticsAldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules.  Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development as topical eye drops for the treatment of ocular inflammation. ADX-102 has now been tested in over 250 patients in Phase 2 clinical trials in dry eye disease, allergic conjunctivitis, and noninfectious anterior uveitis. A dermatologic formulation of ADX-102 is in late-stage clinical development for the treatment of ichthyosis due to Sjögren-Larsson Syndrome, an inborn error of aldehyde metabolism. ADX-102 has not been approved for sale in the U.S. or elsewhere.

Corporate Contact:Stephen TulipanoAldeyra Therapeutics, Inc.Tel: 781-761-4904 ext. 205 [email protected]

Investor Contact:Chris BrinzeyWestwicke PartnersTel: [email protected]

Media Contact:Cammy Duong MacDougall Biomedical Communications Tel: [email protected]

View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-present-at-the-stifel-2017-healthcare-conference-300550338.html

SOURCE Aldeyra Therapeutics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store